Efficacy of Valsartan vs. Perindopril in pulmonary hypertension and endothelial function control in patients with chronic obstructive pulmonary disease
Keywords:obstructive pulmonary disease, angiotensin-II receptor blocker Valsartan, angiotensin converting enzime inhibitor Perindopril pulmonary hypertension, endothelial function
Background: The purpose of this study was evaluation of efficacy of angiotensin-II receptor blocker Valsartan (V) and angiotensin converting enzime inhibitor (ACE) Perindopril (P) in pulmonary hypertension(PH) and endothelial function (EF) control in patients with chronic obstructive pulmonary disease (COPD). Material and methods: There were investigated 31 patients (mean age 52,5±4,14 years), with moderate to severe forms of COPD - initial and after 5 weeks of treatment with V(mean dose 54,5±15,4 mg once-daily) and 31 pacientscu P (mean dose 2,9±1,5 mg), using standard ECG, EcoCG with Doppler, spirometry and ultrasound Duplex (for EF estimation). Results: There were not detected any negative changes on bronchial permeability after treatment with V and P. Considerable significant improvement of endothelial function in parallel with considerable decreasing of pulmonary artery systolic and mean pressure in respons to V and P administration were noticed. Conclusions: Thus, V and P are well-tolerated and high effective in PH and EF control in patients with moderate to severe forms of COPD (p=0,002-0,032).
Hida, W., Tun, Y., Kikuchi, Y. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management. Respiration 2002;7:3-13.
Galie, N., Torbicki, A., Barst, R. et al. Guidelines of diagnoses and treatment of pulmonary arterial hypertnsion. European Heart Journal 2004;25:2243-2278.
Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensinconverting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007; 577:1-6.
Celermajer, DS., Sorensen, KE., Gooch, VM. Non-invasive detection of endothelial dysfunction in children and adults at risc of aterosclerosis. Lancet 1992; 340:1111-1115.
Ceconi C, Fox K, Remme W, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007; 73:237-246.
Ferrari R, Guardigli G, Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drug Ther. 2010; 24:331-339.
Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther. 2005; 3:15-29.
Kitabatake, A., Inoue, M., Asao M. et. al. Non-invasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983; 68:302-309.
Copyright (c) 2023 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.